ID LSHR_HUMAN Reviewed; 699 AA. AC P22888; Q14751; Q15996; Q9UEW9; DT 01-AUG-1991, integrated into UniProtKB/Swiss-Prot. DT 15-DEC-2009, sequence version 4. DT 27-MAR-2024, entry version 234. DE RecName: Full=Lutropin-choriogonadotropic hormone receptor; DE Short=LH/CG-R; DE AltName: Full=Luteinizing hormone receptor; DE Short=LHR; DE Short=LSH-R; DE Flags: Precursor; GN Name=LHCGR; Synonyms=LCGR, LGR2, LHRHR; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-312. RC TISSUE=Ovary; RX PubMed=2244890; DOI=10.1016/0006-291x(90)91552-4; RA Minegish T., Nakamura K., Takakura Y., Miyamoto K., Hasegawa Y., Ibuki Y., RA Igarashi M.; RT "Cloning and sequencing of human LH/hCG receptor cDNA."; RL Biochem. Biophys. Res. Commun. 172:1049-1054(1990). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Ovary; RX PubMed=1922095; DOI=10.1210/mend-5-6-759; RA Jia X.-C., Oikawa M., Bo M., Tanaka T., Ny T., Boime I., Hsueh A.J.W.; RT "Expression of human luteinizing hormone (LH) receptor: interaction with LH RT and chorionic gonadotropin from human but not equine, rat, and ovine RT species."; RL Mol. Endocrinol. 5:759-768(1991). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Thyroid; RX PubMed=2293030; DOI=10.1210/mend-4-8-1264; RA Frazier A.L., Robbins L.S., Stork P.J., Sprengel R., Segaloff D.L., RA Cone R.D.; RT "Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation RT by tissue specific splicing."; RL Mol. Endocrinol. 4:1264-1276(1990). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-GLN-18 INS AND SER-312. RX PubMed=7556872; DOI=10.1016/0303-7207(95)03557-n; RA Atger M., Misrahi M., Sar S., Leflem L., Dessen P., Milgrom E.; RT "Structure of the human luteinizing hormone-choriogonadotropin receptor RT gene: unusual promoter and 5' non-coding regions."; RL Mol. Cell. Endocrinol. 111:113-123(1995). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-54, AND VARIANT LEU-GLN-18 INS. RX PubMed=9858858; DOI=10.1159/000022840; RA Tsai-Morris C.-H., Geng Y., Buczko E., Dehejia A., Dufau M.L.; RT "Genomic distribution and gonadal mRNA expression of two human luteinizing RT hormone receptor exon 1 sequences in random populations."; RL Hum. Hered. 49:48-51(1999). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, SULFATION AT TYR-331, AND MUTAGENESIS OF RP TYR-331 AND TYR-333. RX PubMed=11847099; DOI=10.1093/emboj/21.4.504; RA Costagliola S., Panneels V., Bonomi M., Koch J., Many M.C., Smits G., RA Vassart G.; RT "Tyrosine sulfation is required for agonist recognition by glycoprotein RT hormone receptors."; RL EMBO J. 21:504-513(2002). RN [8] RP PALMITOYLATION AT CYS-643 AND CYS-644, AND MUTAGENESIS OF CYS-643 AND RP CYS-644. RX PubMed=15539429; DOI=10.1210/me.2004-0335; RA Munshi U.M., Clouser C.L., Peegel H., Menon K.M.; RT "Evidence that palmitoylation of carboxyl terminus cysteine residues of the RT human luteinizing hormone receptor regulates postendocytic processing."; RL Mol. Endocrinol. 19:749-758(2005). RN [9] RP 3D-STRUCTURE MODELING OF 51-232. RX PubMed=8747461; DOI=10.1016/s0969-2126(01)00272-6; RA Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H., RA Hendrickson W.A., el Tayar N.; RT "Structural predictions for the ligand-binding region of glycoprotein RT hormone receptors and the nature of hormone-receptor interactions."; RL Structure 3:1341-1353(1995). RN [10] RP VARIANTS FMPP PRO-368 AND VAL-568, AND CHARACTERIZATION OF VARIANT FMPP RP PRO-368. RX PubMed=11134146; DOI=10.1210/jcem.85.12.7071; RA Latronico A.C., Shinozaki H., Guerra G. Jr., Pereira M.A.A., RA Lemos Marini S.H.V., Baptista M.T.M., Arnhold I.J.P., Fanelli F., RA Mendonca B.B., Segaloff D.L.; RT "Gonadotropin-independent precocious puberty due to luteinizing hormone RT receptor mutations in Brazilian boys: a novel constitutively activating RT mutation in the first transmembrane helix."; RL J. Clin. Endocrinol. Metab. 85:4799-4805(2000). RN [11] RP VARIANT FMPP GLY-564. RX PubMed=11391350; DOI=10.1067/mpd.2001.114477; RA Leschek E.W., Chan W.-Y., Diamond D.A., Kaefer M., Jones J., Barnes K.M., RA Cutler G.B. Jr.; RT "Nodular Leydig cell hyperplasia in a boy with familial male-limited RT precocious puberty."; RL J. Pediatr. 138:949-951(2001). RN [12] RP VARIANTS LHR SER-343 AND ARG-543, AND CHARACTERIZATION OF VARIANTS LHR RP SER-343 AND ARG-543. RX PubMed=12050206; DOI=10.1210/jcem.87.6.8523; RA Martens J.W.M., Lumbroso S., Verhoef-Post M., Georget V., Richter-Unruh A., RA Szarras-Czapnik M., Romer T.E., Brunner H.G., Themmen A.P.N., Sultan C.; RT "Mutant luteinizing hormone receptors in a compound heterozygous patient RT with complete Leydig cell hypoplasia: abnormal processing causes signaling RT deficiency."; RL J. Clin. Endocrinol. Metab. 87:2506-2513(2002). RN [13] RP ASSOCIATION OF VARIANT LEU-GLN-18 INS WITH AGE OF BREAST CANCER ONSET. RX PubMed=12679452; DOI=10.1210/jc.2002-021585; RA Powell B.L., Piersma D., Kevenaar M.E., van Staveren I.L., Themmen A.P.N., RA Iacopetta B.J., Berns E.M.J.J.; RT "Luteinizing hormone signaling and breast cancer: polymorphisms and age of RT onset."; RL J. Clin. Endocrinol. Metab. 88:1653-1657(2003). RN [14] RP VARIANT FMPP GLY-578. RX PubMed=7692306; DOI=10.1038/365652a0; RA Shenker A., Laue L., Kosugi S., Merendino J.J. Jr., Minegishi T., RA Cutler G.B. Jr.; RT "A constitutively activating mutation of the luteinizing hormone receptor RT in familial male precocious puberty."; RL Nature 365:652-654(1993). RN [15] RP VARIANTS FMPP ILE-571 AND GLY-578. RX PubMed=8281137; DOI=10.1093/hmg/2.11.1779; RA Kremer H., Mariman E., Otten B.J., Moll G.W. Jr., Stoelinga G.B.A., RA Wit J.M., Jansen M., Drop S.L., Faas B., Ropers H.-H., Brunner H.G.; RT "Cosegregation of missense mutations of the luteinizing hormone receptor RT gene with familial male-limited precocious puberty."; RL Hum. Mol. Genet. 2:1779-1783(1993). RN [16] RP VARIANT FMPP ILE-577. RX PubMed=7757065; DOI=10.1093/hmg/4.2.183; RA Kosugi S., van Dop C., Geffner M.E., Rabl W., Carel J.-C., Chaussain J.-L., RA Mori T., Merendino J.J. Jr., Shenker A.; RT "Characterization of heterogeneous mutations causing constitutive RT activation of the luteinizing hormone receptor in familial male precocious RT puberty."; RL Hum. Mol. Genet. 4:183-188(1995). RN [17] RP VARIANT FMPP VAL-572. RX PubMed=7714085; DOI=10.1210/jcem.80.4.7714085; RA Yano K., Saji M., Hidaka A., Moriya N., Okuno A., Kohn L.D., RA Cutler G.B. Jr.; RT "A new constitutively activating point mutation in the luteinizing RT hormone/choriogonadotropin receptor gene in cases of male-limited RT precocious puberty."; RL J. Clin. Endocrinol. Metab. 80:1162-1168(1995). RN [18] RP VARIANT FMPP VAL-568. RX PubMed=7629248; DOI=10.1210/jcem.80.8.7629248; RA Latronico A.C., Anasti J., Arnhold I.J., Mendonca B.B., Domenice S., RA Albano M.C., Zachman K., Wajchenberg B.L., Tsigos C.; RT "A novel mutation of the luteinizing hormone receptor gene causing male RT gonadotropin-independent precocious puberty."; RL J. Clin. Endocrinol. Metab. 80:2490-2494(1995). RN [19] RP VARIANT LHR PRO-593. RX PubMed=7719343; DOI=10.1038/ng0295-160; RA Kremer H., Kraaij R., Toledo S.P.A., Post M., Fridman J.B., Hayashida C.Y., RA van Reen M., Milgrom E., Ropers H.-H., Mariman E., Themmen A.P.N., RA Brunner H.G.; RT "Male pseudohermaphroditism due to a homozygous missense mutation of the RT luteinizing hormone receptor gene."; RL Nat. Genet. 9:160-164(1995). RN [20] RP VARIANT FMPP ILE-577. RX PubMed=8829636; RX DOI=10.1002/(sici)1098-1004(1996)7:2<164::aid-humu13>3.0.co;2-0; RA Cocco S., Meloni A., Marini M.G., Cao A., Moi P.; RT "A missense (T577I) mutation in the luteinizing hormone receptor gene RT associated with familial male-limited precocious puberty."; RL Hum. Mutat. 7:164-166(1996). RN [21] RP VARIANT FMPP THR-398. RX PubMed=8929952; DOI=10.1136/jmg.33.2.143; RA Evans B.A.J., Bowen D.J., Smith P.J., Clayton P.E., Gregory J.W.; RT "A new point mutation in the luteinising hormone receptor gene in familial RT and sporadic male limited precocious puberty: genotype does not always RT correlate with phenotype."; RL J. Med. Genet. 33:143-147(1996). RN [22] RP VARIANT LHR TYR-616. RX PubMed=8559204; DOI=10.1056/nejm199602223340805; RA Latronico A.C., Anasti J., Arnhold I.J.P., Rapaport R., Mendonca B.B., RA Bloise W., Castro M., Tsigos C., Chrousos G.P.; RT "Testicular and ovarian resistance to luteinizing hormone caused by RT inactivating mutations of the luteinizing hormone-receptor gene."; RL N. Engl. J. Med. 334:507-512(1996). RN [23] RP VARIANT LHR ARG-131. RX PubMed=9215288; DOI=10.1210/jcem.82.7.4039; RA Misrahi M., Meduri G., Pissard S., Bouvattier C., Beau I., Loosfelt H., RA Jolivet A., Rappaport R., Milgrom E., Bougneres P.; RT "Comparison of immunocytochemical and molecular features with the phenotype RT in a case of incomplete male pseudohermaphroditism associated with a RT mutation of the luteinizing hormone receptor."; RL J. Clin. Endocrinol. Metab. 82:2159-2165(1997). RN [24] RP VARIANTS LEU-GLN-18 INS; SER-284 AND ASN-306. RX PubMed=10215412; RA Wu S.-M., Jose M., Hallermeier K., Rennert O.M., Chan W.-Y.; RT "Polymorphisms in the coding exons of the human luteinizing hormone RT receptor gene."; RL Hum. Mutat. 11:333-334(1998). RN [25] RP VARIANT FMPP VAL-373. RX PubMed=9467560; DOI=10.1210/jcem.83.2.4579; RA Gromoll J., Partsch C.-J., Simoni M., Nordhoff V., Sippell W.G., RA Nieschlag E., Saxena B.B.; RT "A mutation in the first transmembrane domain of the lutropin receptor RT causes male precocious puberty."; RL J. Clin. Endocrinol. Metab. 83:476-480(1998). RN [26] RP VARIANT LHR LYS-354. RX PubMed=9626144; DOI=10.1210/jcem.83.6.4855; RA Stavrou S.S., Zhu Y.S., Cai L.Q., Katz M.D., Herrera C., Defillo-Ricart M., RA Imperato-Mcginley J.; RT "A novel mutation of the human luteinizing hormone receptor in 46XY and RT 46XX sisters."; RL J. Clin. Endocrinol. Metab. 83:2091-2098(1998). RN [27] RP VARIANT FMPP ARG-457. RX PubMed=9661624; DOI=10.1210/jcem.83.7.4968; RA Latronico A.C., Abell A.N., Arnhold I.J., Liu X., Lins T.S., Brito V.N., RA Billerbeck A.E., Segaloff D.L., Mendonca B.B.; RT "A unique constitutively activating mutation in third transmembrane helix RT of luteinizing hormone receptor causes sporadic male gonadotropin- RT independent precocious puberty."; RL J. Clin. Endocrinol. Metab. 83:2435-2440(1998). RN [28] RP VARIANT LEU-GLN-18 INS. RX PubMed=9851790; DOI=10.1210/jcem.83.12.5325; RA Rodien P., Cetani F., Costagliola S., Tonacchera M., Duprez L., RA Minegishi T., Govaerts C., Vassart G.; RT "Evidences for an allelic variant of the human LC/CG receptor rather than a RT gene duplication: functional comparison of wild-type and variant RT receptors."; RL J. Clin. Endocrinol. Metab. 83:4431-4434(1998). RN [29] RP VARIANT LHR 608-LEU-VAL-609 DEL. RX PubMed=9514160; DOI=10.1210/mend.12.3.0077; RA Latronico A.C., Chai Y., Arnhold I.J.P., Liu X., Mendonca B.B., RA Segaloff D.L.; RT "A homozygous microdeletion in helix 7 of the luteinizing hormone receptor RT associated with familial testicular and ovarian resistance is due to both RT decreased cell surface expression and impaired effector activation by the RT cell surface receptor."; RL Mol. Endocrinol. 12:442-450(1998). RN [30] RP VARIANT LHR LYS-625. RX PubMed=9626653; DOI=10.1210/mend.12.6.0124; RA Martens J.W., Verhoef-Post M., Abelin N., Ezabella M., Toledo S.P., RA Brunner H.G., Themmen A.P.; RT "A homozygous mutation in the luteinizing hormone receptor causes partial RT Leydig cell hypoplasia: correlation between receptor activity and RT phenotype."; RL Mol. Endocrinol. 12:775-784(1998). RN [31] RP VARIANT LEYDIG CELL TUMOR HIS-578. RX PubMed=10580072; DOI=10.1056/nejm199912023412304; RA Liu G., Duranteau L., Carel J.-C., Monroe J., Doyle D.A., Shenker A.; RT "Leydig-cell tumors caused by an activating mutation of the gene encoding RT the luteinizing hormone receptor."; RL N. Engl. J. Med. 341:1731-1736(1999). RN [32] RP VARIANT LHR PRO-502, AND CHARACTERIZATION OF VARIANT LCH PRO-502. RX PubMed=15372531; DOI=10.1002/ajmg.a.20681; RA Leung M.Y.-K., Al-Muslim O., Wu S.-M., Aziz A., Inam S., Awadh M., RA Rennert O.M., Chan W.-Y.; RT "A novel missense homozygous inactivating mutation in the fourth RT transmembrane helix of the luteinizing hormone receptor in Leydig cell RT hypoplasia."; RL Am. J. Med. Genet. A 130:146-153(2004). RN [33] RP VARIANT LHR PHE-144, AND CHARACTERIZATION OF VARIANT LCH PHE-144. RX PubMed=15472221; DOI=10.1210/jc.2004-0298; RA Richter-Unruh A., Verhoef-Post M., Malak S., Homoki J., Hauffa B.P., RA Themmen A.P.N.; RT "Leydig cell hypoplasia: absent luteinizing hormone receptor cell surface RT expression caused by a novel homozygous mutation in the extracellular RT domain."; RL J. Clin. Endocrinol. Metab. 89:5161-5167(2004). RN [34] RP VARIANT [LARGE SCALE ANALYSIS] ASN-564. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [35] RP VARIANT LHR THR-152, AND CHARACTERIZATION OF VARIANT LHR THR-152. RX PubMed=19551906; DOI=10.1002/humu.21072; RA Qiao J., Han B., Liu B.-L., Chen X., Ru Y., Cheng K.-X., Chen F.-G., RA Zhao S.-X., Liang J., Lu Y.-L., Tang J.-F., Wu Y.-X., Wu W.-L., Chen J.-L., RA Chen M.-D., Song H.-D.; RT "A splice site mutation combined with a novel missense mutation of LHCGR RT cause male pseudohermaphroditism."; RL Hum. Mutat. 30:E855-E865(2009). CC -!- FUNCTION: Receptor for lutropin-choriogonadotropic hormone CC (PubMed:11847099). The activity of this receptor is mediated by G CC proteins which activate adenylate cyclase (PubMed:11847099). CC {ECO:0000269|PubMed:11847099}. CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11847099}; CC Multi-pass membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Additional isoforms seem to exist.; CC Name=Long; CC IsoId=P22888-1; Sequence=Displayed; CC Name=Short; CC IsoId=P22888-2; Sequence=VSP_001962; CC -!- TISSUE SPECIFICITY: Gonadal and thyroid cells. CC -!- PTM: Sulfated. {ECO:0000269|PubMed:11847099}. CC -!- DISEASE: Familial male precocious puberty (FMPP) [MIM:176410]: In FMPP CC the receptor is constitutively activated. {ECO:0000269|PubMed:11134146, CC ECO:0000269|PubMed:11391350, ECO:0000269|PubMed:7629248, CC ECO:0000269|PubMed:7692306, ECO:0000269|PubMed:7714085, CC ECO:0000269|PubMed:7757065, ECO:0000269|PubMed:8281137, CC ECO:0000269|PubMed:8829636, ECO:0000269|PubMed:8929952, CC ECO:0000269|PubMed:9467560, ECO:0000269|PubMed:9661624}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Luteinizing hormone resistance (LHR) [MIM:238320]: An CC autosomal recessive disorder characterized by unresponsiveness to CC luteinizing hormone, defective sexual development in males, and CC defective follicular development and ovulation, amenorrhea and CC infertility in females. Two forms of the disorder have been defined in CC males. Type 1 is a severe form characterized by complete 46,XY male CC pseudohermaphroditism, low testosterone and high luteinizing hormone CC levels, total lack of responsiveness to luteinizing and chorionic CC gonadotropin hormones, lack of breast development, and absent CC development of secondary male sex characteristics. Type 2, a milder CC form, displays a broader range of phenotypic expression ranging from CC micropenis to severe hypospadias. {ECO:0000269|PubMed:12050206, CC ECO:0000269|PubMed:15372531, ECO:0000269|PubMed:15472221, CC ECO:0000269|PubMed:19551906, ECO:0000269|PubMed:7719343, CC ECO:0000269|PubMed:8559204, ECO:0000269|PubMed:9215288, CC ECO:0000269|PubMed:9514160, ECO:0000269|PubMed:9626144, CC ECO:0000269|PubMed:9626653}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. CC FSH/LSH/TSH subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/288/LHR"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M63108; AAA59515.1; -; mRNA. DR EMBL; S57793; AAB19917.2; -; mRNA. DR EMBL; M73746; AAA70231.1; -; mRNA. DR EMBL; X84753; CAA59234.1; -; Genomic_DNA. DR EMBL; X84754; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84755; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84756; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84757; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84758; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84759; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84760; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84761; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84762; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; X84763; CAA59234.1; JOINED; Genomic_DNA. DR EMBL; AC073082; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF082076; AAC98291.1; -; Genomic_DNA. DR EMBL; AF024642; AAB88417.1; -; Genomic_DNA. DR CCDS; CCDS1842.1; -. [P22888-1] DR PIR; A36243; QRHUUT. DR RefSeq; NP_000224.2; NM_000233.3. [P22888-1] DR PDB; 7FIG; EM; 3.90 A; R=28-699. DR PDB; 7FIH; EM; 3.20 A; R=28-699. DR PDB; 7FII; EM; 4.30 A; R=28-699. DR PDB; 7FIJ; EM; 3.80 A; R=28-699. DR PDBsum; 7FIG; -. DR PDBsum; 7FIH; -. DR PDBsum; 7FII; -. DR PDBsum; 7FIJ; -. DR AlphaFoldDB; P22888; -. DR EMDB; EMD-31596; -. DR EMDB; EMD-31597; -. DR EMDB; EMD-31598; -. DR EMDB; EMD-31599; -. DR SMR; P22888; -. DR BioGRID; 110161; 14. DR CORUM; P22888; -. DR MINT; P22888; -. DR STRING; 9606.ENSP00000294954; -. DR BindingDB; P22888; -. DR ChEMBL; CHEMBL1854; -. DR DrugBank; DB06719; Buserelin. DR DrugBank; DB00050; Cetrorelix. DR DrugBank; DB00097; Choriogonadotropin alfa. DR DrugBank; DB09126; Chorionic Gonadotropin (Human). DR DrugBank; DB00014; Goserelin. DR DrugBank; DB00044; Lutropin alfa. DR DrugBank; DB00032; Menotropins. DR DrugCentral; P22888; -. DR GuidetoPHARMACOLOGY; 254; -. DR GlyCosmos; P22888; 6 sites, No reported glycans. DR GlyGen; P22888; 6 sites. DR iPTMnet; P22888; -. DR PhosphoSitePlus; P22888; -. DR SwissPalm; P22888; -. DR BioMuta; LHCGR; -. DR DMDM; 281185513; -. DR MassIVE; P22888; -. DR PaxDb; 9606-ENSP00000294954; -. DR PeptideAtlas; P22888; -. DR Antibodypedia; 4073; 658 antibodies from 37 providers. DR DNASU; 3973; -. DR Ensembl; ENST00000294954.12; ENSP00000294954.6; ENSG00000138039.15. [P22888-1] DR GeneID; 3973; -. DR KEGG; hsa:3973; -. DR MANE-Select; ENST00000294954.12; ENSP00000294954.6; NM_000233.4; NP_000224.2. DR UCSC; uc002rwu.5; human. [P22888-1] DR AGR; HGNC:6585; -. DR CTD; 3973; -. DR DisGeNET; 3973; -. DR GeneCards; LHCGR; -. DR HGNC; HGNC:6585; LHCGR. DR HPA; ENSG00000138039; Tissue enhanced (ovary, testis). DR MalaCards; LHCGR; -. DR MIM; 152790; gene+phenotype. DR MIM; 176410; phenotype. DR MIM; 238320; phenotype. DR neXtProt; NX_P22888; -. DR OpenTargets; ENSG00000138039; -. DR Orphanet; 3000; Familial peripheral male-limited precocious puberty. DR Orphanet; 96265; Leydig cell hypoplasia due to complete LH resistance. DR Orphanet; 96266; Leydig cell hypoplasia due to partial LH resistance. DR Orphanet; 619; NON RARE IN EUROPE: Primary ovarian failure. DR PharmGKB; PA30357; -. DR VEuPathDB; HostDB:ENSG00000138039; -. DR eggNOG; KOG2087; Eukaryota. DR GeneTree; ENSGT00940000157364; -. DR InParanoid; P22888; -. DR OMA; FFRSFTH; -. DR OrthoDB; 1202285at2759; -. DR PhylomeDB; P22888; -. DR TreeFam; TF316814; -. DR PathwayCommons; P22888; -. DR Reactome; R-HSA-375281; Hormone ligand-binding receptors. DR Reactome; R-HSA-418555; G alpha (s) signalling events. DR SignaLink; P22888; -. DR SIGNOR; P22888; -. DR BioGRID-ORCS; 3973; 9 hits in 1158 CRISPR screens. DR ChiTaRS; LHCGR; human. DR GeneWiki; Luteinizing_hormone/choriogonadotropin_receptor; -. DR GenomeRNAi; 3973; -. DR Pharos; P22888; Tclin. DR PRO; PR:P22888; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P22888; Protein. DR Bgee; ENSG00000138039; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 89 other cell types or tissues. DR ExpressionAtlas; P22888; baseline and differential. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0005768; C:endosome; TAS:ProtInc. DR GO; GO:0005615; C:extracellular space; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IEA:Ensembl. DR GO; GO:0051117; F:ATPase binding; IEA:Ensembl. DR GO; GO:0038106; F:choriogonadotropin hormone binding; ISS:BHF-UCL. DR GO; GO:0035472; F:choriogonadotropin hormone receptor activity; ISS:BHF-UCL. DR GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0004964; F:luteinizing hormone receptor activity; IMP:UniProtKB. DR GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl. DR GO; GO:0007190; P:activation of adenylate cyclase activity; ISS:BHF-UCL. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL. DR GO; GO:0050482; P:arachidonic acid secretion; IEA:Ensembl. DR GO; GO:0071371; P:cellular response to gonadotropin stimulus; ISS:BHF-UCL. DR GO; GO:0071373; P:cellular response to luteinizing hormone stimulus; IMP:UniProtKB. DR GO; GO:0050890; P:cognition; IMP:UniProtKB. DR GO; GO:0046544; P:development of secondary male sexual characteristics; IEA:Ensembl. DR GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc. DR GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0042700; P:luteinizing hormone signaling pathway; IMP:UniProtKB. DR GO; GO:0030539; P:male genitalia development; TAS:ProtInc. DR GO; GO:0008584; P:male gonad development; IBA:GO_Central. DR GO; GO:0001541; P:ovarian follicle development; IBA:GO_Central. DR GO; GO:0022602; P:ovulation cycle process; IBA:GO_Central. DR GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL. DR GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl. DR GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IEA:Ensembl. DR GO; GO:0046886; P:positive regulation of hormone biosynthetic process; IEA:Ensembl. DR GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; ISS:BHF-UCL. DR GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl. DR GO; GO:0006622; P:protein targeting to lysosome; IEA:Ensembl. DR GO; GO:0090030; P:regulation of steroid hormone biosynthetic process; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0060065; P:uterus development; IEA:Ensembl. DR CDD; cd15359; 7tmA_LHCGR; 1. DR Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR InterPro; IPR000276; GPCR_Rhodpsn. DR InterPro; IPR017452; GPCR_Rhodpsn_7TM. DR InterPro; IPR002131; Gphrmn_rcpt_fam. DR InterPro; IPR026906; LRR_5. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR002273; LSH_rcpt. DR PANTHER; PTHR24372; GLYCOPROTEIN HORMONE RECEPTOR; 1. DR PANTHER; PTHR24372:SF1; LUTROPIN-CHORIOGONADOTROPIC HORMONE RECEPTOR; 1. DR Pfam; PF00001; 7tm_1; 1. DR Pfam; PF13306; LRR_5; 2. DR PRINTS; PR00373; GLYCHORMONER. DR PRINTS; PR00237; GPCRRHODOPSN. DR PRINTS; PR01144; LSHRECEPTOR. DR SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1. DR SUPFAM; SSF52058; L domain-like; 1. DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1. DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1. DR Genevisible; P22888; HS. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Cell membrane; Disease variant; KW Disulfide bond; G-protein coupled receptor; Glycoprotein; KW Leucine-rich repeat; Lipoprotein; Membrane; Palmitate; Receptor; KW Reference proteome; Repeat; Signal; Sulfation; Transducer; Transmembrane; KW Transmembrane helix. FT SIGNAL 1..26 FT /evidence="ECO:0000255" FT CHAIN 27..699 FT /note="Lutropin-choriogonadotropic hormone receptor" FT /id="PRO_0000012780" FT TOPO_DOM 27..363 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 364..385 FT /note="Helical; Name=1" FT /evidence="ECO:0000255" FT TOPO_DOM 386..395 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 396..416 FT /note="Helical; Name=2" FT /evidence="ECO:0000255" FT TOPO_DOM 417..439 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 440..462 FT /note="Helical; Name=3" FT /evidence="ECO:0000255" FT TOPO_DOM 463..482 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 483..505 FT /note="Helical; Name=4" FT /evidence="ECO:0000255" FT TOPO_DOM 506..525 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 526..549 FT /note="Helical; Name=5" FT /evidence="ECO:0000255" FT TOPO_DOM 550..570 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 571..594 FT /note="Helical; Name=6" FT /evidence="ECO:0000255" FT TOPO_DOM 595..605 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 606..627 FT /note="Helical; Name=7" FT /evidence="ECO:0000255" FT TOPO_DOM 628..699 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 27..66 FT /note="LRRNT" FT REPEAT 96..115 FT /note="LRR 1" FT REPEAT 124..145 FT /note="LRR 2" FT REPEAT 149..171 FT /note="LRR 3" FT REPEAT 175..196 FT /note="LRR 4" FT REPEAT 198..220 FT /note="LRR 5" FT REPEAT 223..244 FT /note="LRR 6" FT MOD_RES 331 FT /note="Sulfotyrosine" FT /evidence="ECO:0000305|PubMed:11847099" FT LIPID 643 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:15539429" FT LIPID 644 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000269|PubMed:15539429" FT CARBOHYD 99 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 174 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 195 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 291 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 299 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 313 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 439..514 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00521" FT VAR_SEQ 227..289 FT /note="Missing (in isoform Short)" FT /evidence="ECO:0000305" FT /id="VSP_001962" FT VARIANT 18 FT /note="Q -> QLQ" FT /evidence="ECO:0000269|PubMed:9851790, FT ECO:0000269|PubMed:9858858" FT /id="VAR_003549" FT VARIANT 131 FT /note="C -> R (in LHR; Leydig cell hypoplasia type 2; FT dbSNP:rs121912527)" FT /evidence="ECO:0000269|PubMed:9215288" FT /id="VAR_010154" FT VARIANT 144 FT /note="V -> F (in LHR; Leydig cell hypoplasia type 1; FT exhibits a marked impairment of human chorionic FT gonadotropin binding; shows the absence of the glycosylated FT cell surface form; the mutant receptor is retained in the FT endoplasmic reticulum; mutant receptors do not migrate to FT the cell surface; dbSNP:rs121912539)" FT /evidence="ECO:0000269|PubMed:15472221" FT /id="VAR_062336" FT VARIANT 152 FT /note="I -> T (in LHR; reveals a marked impairment of human FT chorionic gonadotropin binding and signal transduction)" FT /evidence="ECO:0000269|PubMed:19551906" FT /id="VAR_062337" FT VARIANT 284 FT /note="N -> S" FT /evidence="ECO:0000269|PubMed:10215412" FT /id="VAR_003550" FT VARIANT 291 FT /note="N -> S (in dbSNP:rs12470652)" FT /id="VAR_055922" FT VARIANT 306 FT /note="S -> N" FT /evidence="ECO:0000269|PubMed:10215412" FT /id="VAR_003551" FT VARIANT 312 FT /note="N -> S (in dbSNP:rs2293275)" FT /evidence="ECO:0000269|PubMed:2244890, FT ECO:0000269|PubMed:7556872" FT /id="VAR_060737" FT VARIANT 343 FT /note="C -> S (in LHR; Leydig cell hypoplasia type 1; FT completely devoided of hormone-induced cAMP reporter gene FT activation; although initial translocation to the FT endoplasmic reticulum is normal translocation is halted or FT misrouted and the mutant does not reach the cell surface FT and cannot bind hormone; dbSNP:rs121912536)" FT /evidence="ECO:0000269|PubMed:12050206" FT /id="VAR_010155" FT VARIANT 354 FT /note="E -> K (in LHR; Leydig cell hypoplasia type 1; FT dbSNP:rs121912529)" FT /evidence="ECO:0000269|PubMed:9626144" FT /id="VAR_003552" FT VARIANT 368 FT /note="L -> P (in FMPP; cells expressing the mutation FT display up to a 12-fold increase in basal cAMP production FT compared with cells expressing the same number of cell FT surface wild-type receptor indicating constitutive FT activation of the mutant receptor; dbSNP:rs121912533)" FT /evidence="ECO:0000269|PubMed:11134146" FT /id="VAR_062338" FT VARIANT 373 FT /note="A -> V (in FMPP; dbSNP:rs121912528)" FT /evidence="ECO:0000269|PubMed:9467560" FT /id="VAR_003553" FT VARIANT 398 FT /note="M -> T (in FMPP; dbSNP:rs121912526)" FT /evidence="ECO:0000269|PubMed:8929952" FT /id="VAR_003554" FT VARIANT 457 FT /note="L -> R (in FMPP; dbSNP:rs121912535)" FT /evidence="ECO:0000269|PubMed:9661624" FT /id="VAR_010156" FT VARIANT 502 FT /note="L -> P (in LHR; Leydig cell hypoplasia type 1; shows FT reduced cAMP production and ligand binding; receptor FT trafficking is not affected by the mutation; FT dbSNP:rs121912538)" FT /evidence="ECO:0000269|PubMed:15372531" FT /id="VAR_062339" FT VARIANT 542 FT /note="I -> L (in FMPP; dbSNP:rs121912531)" FT /id="VAR_010157" FT VARIANT 543 FT /note="C -> R (in LHR; Leydig cell hypoplasia type 1; FT completely devoided of hormone-induced cAMP reporter gene FT activation; although initial translocation to the FT endoplasmic reticulum is normal translocation is halted or FT misrouted and the mutant does not reach the cell surface FT and cannot bind hormone; dbSNP:rs121912537)" FT /evidence="ECO:0000269|PubMed:12050206" FT /id="VAR_010158" FT VARIANT 564 FT /note="D -> G (in FMPP; dbSNP:rs121912540)" FT /evidence="ECO:0000269|PubMed:11391350" FT /id="VAR_010159" FT VARIANT 564 FT /note="D -> N (in a breast cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035764" FT VARIANT 568 FT /note="A -> V (in FMPP; dbSNP:rs121912534)" FT /evidence="ECO:0000269|PubMed:11134146, FT ECO:0000269|PubMed:7629248" FT /id="VAR_003555" FT VARIANT 571 FT /note="M -> I (in FMPP; dbSNP:rs121912519)" FT /evidence="ECO:0000269|PubMed:8281137" FT /id="VAR_003556" FT VARIANT 572 FT /note="A -> V (in FMPP; dbSNP:rs121912522)" FT /evidence="ECO:0000269|PubMed:7714085" FT /id="VAR_003557" FT VARIANT 575 FT /note="I -> L (in FMPP; dbSNP:rs767343825)" FT /id="VAR_010160" FT VARIANT 577 FT /note="T -> I (in FMPP; dbSNP:rs121912521)" FT /evidence="ECO:0000269|PubMed:7757065, FT ECO:0000269|PubMed:8829636" FT /id="VAR_003558" FT VARIANT 578 FT /note="D -> E (in FMPP)" FT /id="VAR_010161" FT VARIANT 578 FT /note="D -> G (in FMPP; dbSNP:rs121912518)" FT /evidence="ECO:0000269|PubMed:7692306, FT ECO:0000269|PubMed:8281137" FT /id="VAR_003559" FT VARIANT 578 FT /note="D -> H (in Leydig cell tumor; somatic mutation; FT causes receptor activation and precocious puberty; FT dbSNP:rs121912532)" FT /evidence="ECO:0000269|PubMed:10580072" FT /id="VAR_010162" FT VARIANT 578 FT /note="D -> Y (in FMPP; dbSNP:rs121912532)" FT /id="VAR_010163" FT VARIANT 581 FT /note="C -> R (in FMPP)" FT /id="VAR_010164" FT VARIANT 593 FT /note="A -> P (in LHR; Leydig cell hypoplasia type 1; FT abolishes signal transduction; dbSNP:rs121912520)" FT /evidence="ECO:0000269|PubMed:7719343" FT /id="VAR_003560" FT VARIANT 608..609 FT /note="Missing (in LHR; Leydig cell hypoplasia type 1)" FT /evidence="ECO:0000269|PubMed:9514160" FT /id="VAR_003561" FT VARIANT 616 FT /note="S -> Y (in LHR; Leydig cell hypoplasia type 1; FT micropenis; dbSNP:rs121912525)" FT /evidence="ECO:0000269|PubMed:8559204" FT /id="VAR_003562" FT VARIANT 625 FT /note="I -> K (in LHR; Leydig cell hypoplasia type 2; FT dbSNP:rs121912530)" FT /evidence="ECO:0000269|PubMed:9626653" FT /id="VAR_003563" FT MUTAGEN 331 FT /note="Y->F: Reduces intracellular cAMP accumulation." FT /evidence="ECO:0000269|PubMed:11847099" FT MUTAGEN 333 FT /note="Y->F: No change in intracellular cAMP accumulation." FT /evidence="ECO:0000269|PubMed:11847099" FT MUTAGEN 643 FT /note="C->G: Loss of palmitoylation." FT /evidence="ECO:0000269|PubMed:15539429" FT MUTAGEN 644 FT /note="C->G: Loss of palmitoylation." FT /evidence="ECO:0000269|PubMed:15539429" FT CONFLICT 7 FT /note="A -> P (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 19 FT /note="P -> A (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 27..28 FT /note="EA -> R (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 44..51 FT /note="CPGPTAGL -> APAPRPS (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 68 FT /note="A -> S (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 124 FT /note="R -> G (in Ref. 1; AAA59515 and 4; CAA59234)" FT /evidence="ECO:0000305" FT CONFLICT 262..263 FT /note="RE -> KQ (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 270 FT /note="E -> R (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 274 FT /note="T -> H (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 290 FT /note="Q -> L (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 311..323 FT /note="Missing (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 448 FT /note="F -> L (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 540 FT /note="F -> L (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT CONFLICT 649 FT /note="E -> DP (in Ref. 3; AAA70231)" FT /evidence="ECO:0000305" FT STRAND 53..58 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 66..71 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 77..82 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 91..93 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 102..105 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 127..133 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 151..157 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 166..171 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 172..175 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 177..180 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 193..203 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 215..218 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 219..222 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 225..228 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 239..241 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 242..244 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 246..249 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 262..264 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 276..282 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 343..345 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 360..372 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 375..385 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 393..421 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 422..424 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 426..434 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 437..469 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 480..497 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 500..503 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 522..553 FT /evidence="ECO:0007829|PDB:7FIH" FT STRAND 556..559 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 561..563 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 564..593 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 601..611 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 614..623 FT /evidence="ECO:0007829|PDB:7FIH" FT TURN 624..626 FT /evidence="ECO:0007829|PDB:7FIH" FT HELIX 628..641 FT /evidence="ECO:0007829|PDB:7FIH" SQ SEQUENCE 699 AA; 78643 MW; 2E3D93F4621BA842 CRC64; MKQRFSALQL LKLLLLLQPP LPRALREALC PEPCNCVPDG ALRCPGPTAG LTRLSLAYLP VKVIPSQAFR GLNEVIKIEI SQIDSLERIE ANAFDNLLNL SEILIQNTKN LRYIEPGAFI NLPRLKYLSI CNTGIRKFPD VTKVFSSESN FILEICDNLH ITTIPGNAFQ GMNNESVTLK LYGNGFEEVQ SHAFNGTTLT SLELKENVHL EKMHNGAFRG ATGPKTLDIS STKLQALPSY GLESIQRLIA TSSYSLKKLP SRETFVNLLE ATLTYPSHCC AFRNLPTKEQ NFSHSISENF SKQCESTVRK VNNKTLYSSM LAESELSGWD YEYGFCLPKT PRCAPEPDAF NPCEDIMGYD FLRVLIWLIN ILAIMGNMTV LFVLLTSRYK LTVPRFLMCN LSFADFCMGL YLLLIASVDS QTKGQYYNHA IDWQTGSGCS TAGFFTVFAS ELSVYTLTVI TLERWHTITY AIHLDQKLRL RHAILIMLGG WLFSSLIAML PLVGVSNYMK VSICFPMDVE TTLSQVYILT ILILNVVAFF IICACYIKIY FAVRNPELMA TNKDTKIAKK MAILIFTDFT CMAPISFFAI SAAFKVPLIT VTNSKVLLVL FYPINSCANP FLYAIFTKTF QRDFFLLLSK FGCCKRRAEL YRRKDFSAYT SNCKNGFTGS NKPSQSTLKL STLHCQGTAL LDKTRYTEC //